Market Overview:
The global histone deacetylase 1 market is expected to register a CAGR of XX% during the forecast period 2018-2030. The histone deacetylase 1 market is segmented on the basis of type, application and region. On the basis of type, RCY-1305, HG-3001, CS-3158, ACY-957 and ST-3595 are some of the key players in this market. On the basis of application, alopecia, endometrial cancer myelofibrosis neurology skin cancer are some of the key applications in this market. North America dominates this market followed by Europe and Asia Pacific respectively.
Product Definition:
Histone deacetylase 1 is an enzyme that removes acetyl groups from histones, which are proteins that help organize DNA into chromatin. Histone deacetylases play a role in regulating gene expression.
RCY-1305:
RCY-1305 is a novel oral drug that is developed by Roche and it's an acetylated version of Rituximab. It's a Monoclonal Antibody Drug Conjugate (MADC) which targets and eliminates B-cell malignancies.
HG-3001:
HG-3001 is a novel oral hypoglycemic drug that decreases the production of cytokines by immune cells. It has been found to be more effective than any other anti-inflammatory agent in treating patients with moderate to severe plaque psoriasis. The drug was developed by Eli Lilly and Company and was first approved in Japan in 2010, where it received the status of an innovator product.
Application Insights:
The application segment includes alopecia, endometrial cancer, myelofibrosis, neurology and skin cancer. Alopecia was the largest revenue generating segment in 2017. Histone deacetylase inhibitor is used for the treatment of hair loss associated with various diseases such as alopecia areata (AA), Androgenetic Alopecia (AGA) and Telogen Effluvium (TE). The growing prevalence of AA is one of the major factors contributing to market growth. According to a study conducted by NCBI in 2014, it has been estimated that approximately 1% to 2% people aged over 50 years suffer from AA. In addition, another study states that around 5 million people in America suffer from mild-moderate hair thinning problems due to genetic reasons alone. Therefore, increasing number of histone deacetylase inhibitor prescriptions for hair loss treatment is expected to boost market growth during the forecast period 2018-2030 period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players undertaking extensive research activities is anticipated to drive the regional market further. In addition, increasing prevalence of skin cancer and alopecia are contributing towards growth in this region. For instance, according to statistics published by American Cancer Society in 2018, it is estimated that around 2 million new cases will be diagnosed in U.S., with skin cancer being the most prevalent form and 1 person dies due to it every 45 seconds in U.S.
Growth Factors:
- Increasing research and development expenditure by pharmaceutical and biotechnology companies for the discovery of novel HDAC inhibitors for the treatment of various diseases.
- Growing demand for histone deacetylase inhibitors in cancer therapy as they play a crucial role in tumor suppression.
- Rising prevalence of chronic diseases such as cancer, autoimmune disorders, and neurological disorders which is expected to drive the demand for HDAC inhibitors over the forecast period.
- increasing geriatric population base across the globe which is more susceptible to develop chronic diseases will fuel growth of Histone Deacetylase 1 market during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase 1 Market Research Report
By Type
RCY-1305, HG-3001, CS-3158, ACY-957, ST-3595, Others
By Application
Alopecia, Endometrial Cancer, Myelofibrosis, Neurology, Skin Cancer, Others
By Companies
SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc., GlaxoSmithKline Plc, HitGen LTD, IRBM Science Park SpA, Italfarmaco S.p.A., MEI Pharma, Inc., Merck & Co., Inc., SC AG, Oncolys BioPharma Inc., Sigma-Tau S.p.A., Syndax Pharmaceuticals, Inc., TetraLogic Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
178
Number of Tables & Figures
125
Customization Available
Yes, the report can be customized as per your need.
Global Histone Deacetylase 1 Market Report Segments:
The global Histone Deacetylase 1 market is segmented on the basis of:
Types
RCY-1305, HG-3001, CS-3158, ACY-957, ST-3595, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alopecia, Endometrial Cancer, Myelofibrosis, Neurology, Skin Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- SC AG
- Acetylon Pharmaceuticals, Inc.
- Chipscreen Biosciences Ltd
- Curis, Inc.
- GlaxoSmithKline Plc
- HitGen LTD
- IRBM Science Park SpA
- Italfarmaco S.p.A.
- MEI Pharma, Inc.
- Merck & Co., Inc.
- SC AG
- Oncolys BioPharma Inc.
- Sigma-Tau S.p.A.
- Syndax Pharmaceuticals, Inc.
- TetraLogic Pharmaceuticals
Highlights of The Histone Deacetylase 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RCY-1305
- HG-3001
- CS-3158
- ACY-957
- ST-3595
- Others
- By Application:
- Alopecia
- Endometrial Cancer
- Myelofibrosis
- Neurology
- Skin Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase 1 (HDAC1) is an enzyme that catalyzes the chemical reaction of removing a acetyl group from histones. This process can lead to the alteration or removal of certain histone proteins, which can have a variety of effects on gene expression. HDAC1 is particularly important in regulating gene expression during development and in response to stress or disease conditions.
Some of the major companies in the histone deacetylase 1 market are SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc., GlaxoSmithKline Plc, HitGen LTD, IRBM Science Park SpA, Italfarmaco S.p.A., MEI Pharma, Inc., Merck & Co., Inc., SC AG, Oncolys BioPharma Inc., Sigma-Tau S.p.A., Syndax Pharmaceuticals, Inc., TetraLogic Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Histone Deacetylase 1 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Histone Deacetylase 1 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Histone Deacetylase 1 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Histone Deacetylase 1 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Histone Deacetylase 1 Market Size & Forecast, 2020-2028
4.5.1 Histone Deacetylase 1 Market Size and Y-o-Y Growth
4.5.2 Histone Deacetylase 1 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 RCY-1305
5.2.2 HG-3001
5.2.3 CS-3158
5.2.4 ACY-957
5.2.5 ST-3595
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Alopecia
6.2.2 Endometrial Cancer
6.2.3 Myelofibrosis
6.2.4 Neurology
6.2.5 Skin Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Histone Deacetylase 1 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Histone Deacetylase 1 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 RCY-1305
9.6.2 HG-3001
9.6.3 CS-3158
9.6.4 ACY-957
9.6.5 ST-3595
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Alopecia
9.10.2 Endometrial Cancer
9.10.3 Myelofibrosis
9.10.4 Neurology
9.10.5 Skin Cancer
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 RCY-1305
10.6.2 HG-3001
10.6.3 CS-3158
10.6.4 ACY-957
10.6.5 ST-3595
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Alopecia
10.10.2 Endometrial Cancer
10.10.3 Myelofibrosis
10.10.4 Neurology
10.10.5 Skin Cancer
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 RCY-1305
11.6.2 HG-3001
11.6.3 CS-3158
11.6.4 ACY-957
11.6.5 ST-3595
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Alopecia
11.10.2 Endometrial Cancer
11.10.3 Myelofibrosis
11.10.4 Neurology
11.10.5 Skin Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 RCY-1305
12.6.2 HG-3001
12.6.3 CS-3158
12.6.4 ACY-957
12.6.5 ST-3595
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Alopecia
12.10.2 Endometrial Cancer
12.10.3 Myelofibrosis
12.10.4 Neurology
12.10.5 Skin Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 RCY-1305
13.6.2 HG-3001
13.6.3 CS-3158
13.6.4 ACY-957
13.6.5 ST-3595
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Alopecia
13.10.2 Endometrial Cancer
13.10.3 Myelofibrosis
13.10.4 Neurology
13.10.5 Skin Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Histone Deacetylase 1 Market: Competitive Dashboard
14.2 Global Histone Deacetylase 1 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 SC AG
14.3.2 Acetylon Pharmaceuticals, Inc.
14.3.3 Chipscreen Biosciences Ltd
14.3.4 Curis, Inc.
14.3.5 GlaxoSmithKline Plc
14.3.6 HitGen LTD
14.3.7 IRBM Science Park SpA
14.3.8 Italfarmaco S.p.A.
14.3.9 MEI Pharma, Inc.
14.3.10 Merck & Co., Inc.
14.3.11 SC AG
14.3.12 Oncolys BioPharma Inc.
14.3.13 Sigma-Tau S.p.A.
14.3.14 Syndax Pharmaceuticals, Inc.
14.3.15 TetraLogic Pharmaceuticals
